MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Daiichi Sankyo and Merck Announce Global Development and Commercialization Partnership for MK-6070

NextEdge Admin

07 Aug 2024

1 min 48 sec

Merck,small cell lung cancer,neuroendocrine tumors

Daiichi Sankyo and Merck , known as MSD outside the U.S. and Canada, have expanded their global co-development and co-commercialization agreement to include Merck’s MK-6070, an investigational DLL3-targeting T-cell engager. This partnership excludes Japan, where Merck retains exclusive rights, and Merck will handle all manufacturing and supply for MK-6070.

MK-6070, acquired through Merck’s acquisition of Harpoon Therapeutics, is currently in a Phase 1/2 clinical trial (NCT04471727) targeting DLL3, highly expressed in small cell lung cancer (SCLC) and neuroendocrine tumors. The companies plan to evaluate MK-6070 in combination with ifinatamab deruxtecan (I-DXd) for SCLC and other potential combinations.

Ken Takeshita, MD, global head of R&D at Daiichi Sankyo, stated that this expansion aligns with their strategy to set new cancer care standards. He highlighted the synergy between MK-6070 and their established antibody-drug conjugate collaboration, particularly with I-DXd.

Dr. Dean Y. Li, president of Merck Research Laboratories, emphasized the urgent need for new treatments for aggressive SCLC. He expressed enthusiasm for the expanded collaboration with Daiichi Sankyo and the potential of combining MK-6070 and ifinatamab deruxtecan in treating SCLC and other cancers.